November 19, 2020 | Alok Kanti, Bayer Canada, COVID-19, Impetus Digital, Leadership, Natalie Yeadon, Pandemic, Pharma, digital health, health technologies
Alok Kanti, President & CEO of Bayer Canada, discusses a variety of topics, including his experience with leading an entire organization through the COVID-19 pandemic and where he sees digital health technologies play the biggest roles in the new normal.
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
To set their Phase II clinical trial of a novel anti-cancer compound up for success, our client sought early multidisciplinary insights on current unmet needs, as well as feedback on their preclinical…
Unlock the potential of asynchronous virtual meetings with the first tip from our “Top 10 Tips for Optimizing Asynchronous Virtual Meetings”.
We’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put the idea of in-person meetings being superior to rest.
This quick video covers #9 of our Top 10 Most Important Advisor Questions, shedding light on the complexities of local and national regulatory issues in the Pharma and Life Sciences…
Register now for one of our upcoming webinars (February 26-28)
In this quick clip, we highlight a vital tip from our ‘Top 10 Most Important Advisor Questions’ – essential for enhancing your virtual collaboration strategies in Pharma and Life Sciences….
Learn how our client executed a series of 3 virtual touchpoints with 5 rare disease patient advocates to:- Develop a better understanding of the current treatment landscape and lived patient…
In this video, we explore another crucial aspect of advisor questions when developing your virtual advisory board touchpoints – a key component for success in today’s diverse healthcare landscape. 7….
Join us for a look at the top-5 emerging virtual collaboration trends…
As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here’s another one to keep in…
